MGI Purchase Of Guilford Will Create Two-Product Acute Care Sales Force
This article was originally published in The Pink Sheet Daily
Executive Summary
Reps will target surgeons and anesthesiologists to promote Aloxi post-operative nausea treatment and the pipeline sedative Aquavan. The $177.5 mil. merger is expected to close in the fourth quarter.
You may also be interested in...
MGI Pharma Files Aquavan NDA
Drug for mild to moderate sedation could achieve peak sales of $400 million, company tells "The Pink Sheet" DAILY.
MGI Pharma Files Aquavan NDA
Drug for mild to moderate sedation could achieve peak sales of $400 million, company tells "The Pink Sheet" DAILY.
Gliadel Ad Features Misleading Efficacy Claims – DDMAC
Two-page journal ad includes unsubstantiated claims that high-grade malignant melanoma treatment “works at day 1,” FDA says.